Article Information
History
- August 9, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Jillian L. Kadota*,1,2,
- Allan Musinguzi*,3,
- Hélène E. Aschmann1,2,
- Lydia Akello3,
- Fred Welishe3,
- Jane Nakimuli3,
- Christopher A. Berger1,2,
- Noah Kiwanuka4,
- Patrick PJ Phillips1,2,
- Achilles Katamba5,6,
- David W. Dowdy7,
- Adithya Cattamanchi**,2,9,§ and
- Fred C. Semitala**,3,8,10
- 1Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco CA USA
- 2Center for Tuberculosis, University of California San Francisco, San Francisco CA USA
- 3Infectious Diseases Research Collaboration, Kampala, Uganda
- 4Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda
- 5Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
- 6Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda
- 7Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 8Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
- 9Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Orange CA USA
- 10Makerere University Joint AIDS Program, Kampala, Uganda
- ↵§Corresponding author:
Adithya Cattamanchi, University of California Irvine, 333 City Blvd. West, Suite 400, Orange, CA 92868 acattama{at}hs.uci.edu
Posted August 09, 2024.
Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda
